EA201792185A2 - Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3) - Google Patents
Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)Info
- Publication number
- EA201792185A2 EA201792185A2 EA201792185A EA201792185A EA201792185A2 EA 201792185 A2 EA201792185 A2 EA 201792185A2 EA 201792185 A EA201792185 A EA 201792185A EA 201792185 A EA201792185 A EA 201792185A EA 201792185 A2 EA201792185 A2 EA 201792185A2
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- expression
- activator
- transcription
- modulation
- signal transducer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Здесь раскрыты антисмысловые соединения и способы снижения экспрессии мРНК и белка STAT3. Такие способы, соединения и композиции являются полезными для лечения, предупреждения или облегчения гиперпролиферативных заболеваний.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161471001P | 2011-04-01 | 2011-04-01 | |
US201161471015P | 2011-04-01 | 2011-04-01 | |
US201161471035P | 2011-04-01 | 2011-04-01 | |
US201161471045P | 2011-04-01 | 2011-04-01 | |
US201161558308P | 2011-11-10 | 2011-11-10 | |
US201161558316P | 2011-11-10 | 2011-11-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201792185A2 true EA201792185A2 (ru) | 2018-06-29 |
EA201792185A3 EA201792185A3 (ru) | 2018-10-31 |
Family
ID=46932413
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201391329A EA029317B1 (ru) | 2011-04-01 | 2012-03-30 | Одноцепочечный антисмысловой модифицированный олигонуклеотид для ингибирования экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3) и его применение для лечения гиперпролиферативного заболевания |
EA201792185A EA201792185A3 (ru) | 2011-04-01 | 2012-03-30 | Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201391329A EA029317B1 (ru) | 2011-04-01 | 2012-03-30 | Одноцепочечный антисмысловой модифицированный олигонуклеотид для ингибирования экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3) и его применение для лечения гиперпролиферативного заболевания |
Country Status (33)
Country | Link |
---|---|
US (4) | US8816056B2 (ru) |
EP (2) | EP3466960A3 (ru) |
JP (1) | JP5943993B2 (ru) |
KR (2) | KR102050469B1 (ru) |
CN (2) | CN107012144A (ru) |
AU (1) | AU2012236206C1 (ru) |
BR (1) | BR112013024768B1 (ru) |
CA (1) | CA2831915C (ru) |
CL (1) | CL2013002773A1 (ru) |
CO (1) | CO6821885A2 (ru) |
CY (1) | CY1121460T1 (ru) |
DK (1) | DK2697243T3 (ru) |
DO (1) | DOP2013000216A (ru) |
EA (2) | EA029317B1 (ru) |
EC (1) | ECSP13012909A (ru) |
ES (1) | ES2709495T3 (ru) |
GT (1) | GT201300232A (ru) |
HR (1) | HRP20182169T1 (ru) |
HU (1) | HUE042173T2 (ru) |
IL (2) | IL228569A (ru) |
LT (1) | LT2697243T (ru) |
ME (1) | ME03317B (ru) |
MX (1) | MX340086B (ru) |
MY (1) | MY163004A (ru) |
NI (1) | NI201300101A (ru) |
PE (2) | PE20181518A1 (ru) |
PL (1) | PL2697243T3 (ru) |
PT (1) | PT2697243T (ru) |
RS (1) | RS58489B1 (ru) |
SG (1) | SG193504A1 (ru) |
SI (1) | SI2697243T1 (ru) |
WO (1) | WO2012135736A2 (ru) |
ZA (1) | ZA201308153B (ru) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20181518A1 (es) | 2011-04-01 | 2018-09-21 | Ionis Pharmaceuticals Inc | Modulacion de la expresion del transductor de senales y activador de la transcripcion 3 (stat3) |
US9410156B2 (en) * | 2012-03-28 | 2016-08-09 | Somalogic, Inc. | Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions |
CA2888486A1 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | METHODS OF MONITORING C9ORF72 EXPRESSION |
PL2920308T3 (pl) | 2012-10-31 | 2019-06-28 | Ionis Pharmaceuticals, Inc. | Leczenie nowotworu |
SG10201801813YA (en) | 2013-05-01 | 2018-04-27 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating apolipoprotein c-iii expression |
ES2787600T3 (es) * | 2013-07-02 | 2020-10-16 | Ionis Pharmaceuticals Inc | Moduladores del receptor de la hormona del crecimiento |
CA2920508C (en) | 2013-09-09 | 2024-01-16 | Somalogic, Inc. | Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders |
MY192689A (en) | 2013-10-11 | 2022-09-01 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
US9994855B2 (en) | 2014-05-01 | 2018-06-12 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
CA2943894A1 (en) | 2014-05-01 | 2015-11-05 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating complement factor b expression |
EP3137605B1 (en) | 2014-05-01 | 2020-10-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
EP3189141B1 (en) * | 2014-09-02 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Antisense oligonucleotides targeting 3'utr region of a20 |
AU2015335029B2 (en) | 2014-10-24 | 2021-09-23 | Astrazeneca Ab | Combination |
US9605263B2 (en) | 2015-04-16 | 2017-03-28 | Ionis Pharmaceuticals, Inc. | Compositions for modulating C9ORF72 expression |
WO2017004357A1 (en) * | 2015-07-02 | 2017-01-05 | City Of Hope | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof |
CA2991894A1 (en) | 2015-07-10 | 2017-01-19 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (dgat2) |
WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
WO2017078099A1 (ja) | 2015-11-06 | 2017-05-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
JP7486920B2 (ja) | 2015-11-06 | 2024-05-20 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | アポリポタンパク質(a)発現の調節 |
SG11201809002RA (en) | 2016-04-29 | 2018-11-29 | Univ Nanyang Tech | G-quadruplex-containing antisense oligonucleotides |
CN105985961B (zh) * | 2016-07-22 | 2019-01-29 | 广西师范大学 | 抑制EGFR基因表达的siRNA及其应用 |
KR20190053905A (ko) | 2016-09-16 | 2019-05-20 | 바이오-패쓰 홀딩스 인크. | 리포솜 안티센스 올리고뉴클레오타이드와의 병용 요법 |
CN109661233A (zh) | 2016-10-06 | 2019-04-19 | Ionis 制药公司 | 缀合低聚化合物的方法 |
WO2018102397A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
EP3612159A4 (en) * | 2017-04-19 | 2021-01-20 | Bio-Path Holdings, Inc. | P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION |
GB2574793B (en) * | 2018-05-01 | 2022-09-28 | Flexenable Ltd | Organic liquid crystal display device with one or more oxygen permeable films |
TW202023573A (zh) * | 2018-09-19 | 2020-07-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
WO2021030769A1 (en) * | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with nras antisense oligonucleotides |
CN114514037A (zh) | 2019-09-30 | 2022-05-17 | 阿斯利康(瑞典)有限公司 | 用于癌症的组合治疗 |
EP4058152A4 (en) * | 2019-11-14 | 2024-05-08 | The Board of Regents of the University of Oklahoma | PROSTATE CANCER TREATMENTS USING OLIGONUCLEOTIDES INTERFERENCE |
CN114908094B (zh) * | 2022-05-31 | 2024-03-12 | 中山大学 | 一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用 |
WO2024003241A1 (en) | 2022-06-30 | 2024-01-04 | Astrazeneca Ab | Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
AU2580892A (en) | 1991-09-05 | 1993-04-05 | Isis Pharmaceuticals, Inc. | Determination of oligonucleotides for therapeutics, diagnostics and research reagents |
WO1994014226A1 (en) | 1992-12-14 | 1994-06-23 | Honeywell Inc. | Motor system with individually controlled redundant windings |
US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
EP0676469A3 (en) | 1994-04-04 | 1998-03-25 | Tadamitsu Kishimoto | Transcription Factor APRF |
WO1995031574A1 (en) | 1994-05-16 | 1995-11-23 | Brigham And Women's Hospital | Processes, apparatus and compositions for characterizing nucleotide sequences |
EP0717110A1 (en) | 1994-11-22 | 1996-06-19 | Association Francaise Contre Les Myopathies | LGMD gene |
US5877021A (en) | 1995-07-07 | 1999-03-02 | Ribozyme Pharmaceuticals, Inc. | B7-1 targeted ribozymes |
US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
AU4723797A (en) | 1997-01-10 | 1998-08-03 | Tadamitsu Kishimoto | Novel stat function-regulatory protein |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
KR100414936B1 (ko) | 1997-09-12 | 2004-01-13 | 엑시콘 에이/에스 | 이환 및 삼환 뉴클레오시드, 뉴클레오타이드 및올리고뉴클레오타이드 동족체 |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
US6159694A (en) | 1999-04-08 | 2000-12-12 | Isis Pharmaceuticals Inc. | Antisense modulation of stat3 expression |
JP2002543214A (ja) | 1999-05-04 | 2002-12-17 | エクシコン エ/エス | L−リボ−lna類縁体 |
US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
AU1368300A (en) | 1999-07-09 | 2001-01-30 | Universite De Liege | Cold-active beta galactosidase, the process for its preparation and the use thereof |
US6248586B1 (en) | 1999-12-17 | 2001-06-19 | Isis Pharmaceuticals, Inc. | Antisense modulation of PKA catalytic subunit C-alpha expression |
CA2446619C (en) | 2001-05-11 | 2011-04-26 | Elan Corporation, Plc | Permeation enhancers |
US20050196781A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA) |
JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
JP2005516586A (ja) | 2001-07-20 | 2005-06-09 | ボード オブ トラスティーズ オブ ザ ユニヴァースティ オブ イリノイ | 癌の処置に対する遺伝子標的を同定するための試薬および方法 |
US7259150B2 (en) * | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
CA2504929C (en) | 2002-11-05 | 2014-07-22 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
EP2305812A3 (en) | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
ES2382807T3 (es) | 2003-08-28 | 2012-06-13 | Takeshi Imanishi | Nuevos ácidos nucleicos artificiales del tipo de enlace N-O con reticulación |
CA2538252C (en) | 2003-09-18 | 2014-02-25 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
CN1733916A (zh) * | 2005-07-01 | 2006-02-15 | 中国人民解放军第三军医大学 | 抑制Stat3基因表达的siRNA及其制备方法 |
CN100357436C (zh) * | 2005-07-01 | 2007-12-26 | 中国人民解放军第三军医大学 | 抑制Stat3基因表达的siRNA及其制备方法 |
JP5342881B2 (ja) | 2006-01-27 | 2013-11-13 | アイシス ファーマシューティカルズ, インコーポレーテッド | 6−修飾された二環式核酸類似体 |
AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
EP2125852B1 (en) | 2007-02-15 | 2016-04-06 | Ionis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
WO2008109494A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting stat3 gene expression and uses thereof |
US20100105134A1 (en) | 2007-03-02 | 2010-04-29 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
AU2008260277C1 (en) | 2007-05-30 | 2014-04-17 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
US8278426B2 (en) | 2007-06-08 | 2012-10-02 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
WO2009006478A2 (en) | 2007-07-05 | 2009-01-08 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
EP2190994A2 (en) * | 2007-09-17 | 2010-06-02 | Intradigm Corporation | Compositions comprising stat3 sirna and methods of use thereof |
AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
PE20181518A1 (es) | 2011-04-01 | 2018-09-21 | Ionis Pharmaceuticals Inc | Modulacion de la expresion del transductor de senales y activador de la transcripcion 3 (stat3) |
US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
PL2920308T3 (pl) | 2012-10-31 | 2019-06-28 | Ionis Pharmaceuticals, Inc. | Leczenie nowotworu |
US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2012
- 2012-03-30 PE PE2018001314A patent/PE20181518A1/es unknown
- 2012-03-30 EP EP18201757.4A patent/EP3466960A3/en not_active Withdrawn
- 2012-03-30 BR BR112013024768-1A patent/BR112013024768B1/pt active IP Right Grant
- 2012-03-30 WO PCT/US2012/031642 patent/WO2012135736A2/en active Application Filing
- 2012-03-30 ES ES12763390T patent/ES2709495T3/es active Active
- 2012-03-30 SI SI201231497T patent/SI2697243T1/sl unknown
- 2012-03-30 KR KR1020137028986A patent/KR102050469B1/ko active IP Right Grant
- 2012-03-30 CA CA2831915A patent/CA2831915C/en active Active
- 2012-03-30 SG SG2013069935A patent/SG193504A1/en unknown
- 2012-03-30 MX MX2013011423A patent/MX340086B/es active IP Right Grant
- 2012-03-30 PE PE2013002156A patent/PE20142463A1/es active IP Right Grant
- 2012-03-30 AU AU2012236206A patent/AU2012236206C1/en active Active
- 2012-03-30 US US13/436,558 patent/US8816056B2/en active Active
- 2012-03-30 EA EA201391329A patent/EA029317B1/ru not_active IP Right Cessation
- 2012-03-30 PL PL12763390T patent/PL2697243T3/pl unknown
- 2012-03-30 JP JP2014502867A patent/JP5943993B2/ja active Active
- 2012-03-30 PT PT12763390T patent/PT2697243T/pt unknown
- 2012-03-30 RS RS20190022A patent/RS58489B1/sr unknown
- 2012-03-30 MY MYPI2013701834A patent/MY163004A/en unknown
- 2012-03-30 HU HUE12763390A patent/HUE042173T2/hu unknown
- 2012-03-30 CN CN201611204855.1A patent/CN107012144A/zh active Pending
- 2012-03-30 DK DK12763390.7T patent/DK2697243T3/en active
- 2012-03-30 LT LTEP12763390.7T patent/LT2697243T/lt unknown
- 2012-03-30 KR KR1020197021858A patent/KR20190092590A/ko active IP Right Grant
- 2012-03-30 EA EA201792185A patent/EA201792185A3/ru unknown
- 2012-03-30 EP EP12763390.7A patent/EP2697243B1/en active Active
- 2012-03-30 ME MEP-2019-20A patent/ME03317B/me unknown
- 2012-03-30 CN CN201280026065.2A patent/CN103562215B/zh active Active
-
2013
- 2013-09-26 CL CL2013002773A patent/CL2013002773A1/es unknown
- 2013-09-26 CO CO13229252A patent/CO6821885A2/es unknown
- 2013-09-27 DO DO2013000216A patent/DOP2013000216A/es unknown
- 2013-09-27 GT GT201300232A patent/GT201300232A/es unknown
- 2013-09-29 IL IL228569A patent/IL228569A/en active IP Right Grant
- 2013-09-30 EC ECSP13012909 patent/ECSP13012909A/es unknown
- 2013-09-30 NI NI201300101A patent/NI201300101A/es unknown
- 2013-10-31 ZA ZA2013/08153A patent/ZA201308153B/en unknown
-
2014
- 2014-07-23 US US14/338,880 patent/US9359608B2/en active Active
-
2016
- 2016-05-09 US US15/149,642 patent/US10479993B2/en active Active
-
2017
- 2017-11-22 IL IL255858A patent/IL255858A/en unknown
-
2018
- 2018-12-20 HR HRP20182169TT patent/HRP20182169T1/hr unknown
-
2019
- 2019-01-18 CY CY20191100068T patent/CY1121460T1/el unknown
- 2019-10-08 US US16/595,924 patent/US20200385716A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792185A3 (ru) | Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3) | |
EA201390711A1 (ru) | Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения | |
BR112013021134A2 (pt) | moduladores e métodos de uso | |
MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
BR112013014119A8 (pt) | Novos moduladores e métodos de uso | |
BR112013005116A2 (pt) | moduladores e métodos de uso | |
EA201390214A1 (ru) | Гетероарилы и их применение | |
EA201391389A1 (ru) | Кристаллы антител против склеростина и составы на их основе | |
EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
EA201490922A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
BR112013004776A2 (pt) | moduladores de proteína notum e métodos de uso | |
EA201490042A1 (ru) | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak | |
EA201270100A1 (ru) | Пиримидиноны в качестве ингибиторов pi3k | |
EP3715457A3 (en) | Modulation of prekallikrein (pkk) expression | |
PH12014501122A1 (en) | Methods of treatment using an antibody against interferon gamma | |
MA35660B1 (fr) | Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile | |
EA201270149A1 (ru) | Ингибиторы bace | |
IN2012DN03883A (ru) | ||
EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
EA201790882A1 (ru) | Способы и композиции для терапии рака печени | |
EA201200559A1 (ru) | Способы назначения терапии пирфенидоном | |
ATE505191T1 (de) | Ectoin zur behandlung von vascular leaks | |
EA201592238A1 (ru) | Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма | |
GEP20166474B (en) | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors | |
EA201490688A1 (ru) | 2-тиопиримидиноны |